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Background: to compare the effect of aliskiren and amlodipine on QT dispersion in hypertensive diabetic patients.
Methods: after a two week placebo period 86 mild hypertensive patients with well controlled type 2 diabetes (HbA1c < 7%) were randomized to 
aliskiren 300 mg or amlodipine 10 mg for 24 weeks; hydrochlorothiazide 12.5 mg was added after 12 weeks if BP remained uncontrolled. At the end 
of the placebo period and of the treatment period BP was evaluated and an ECG was recorded using a paper speed of 50 mm/s. The QT intervals 
were measured manually in all the 12 leads in blinded fashion and 3 consecutive QT intervals were measured and averaged for each lead. The QT 
dispersion was corrected for the heart rate (QTc).
Results: the two treatments induced a significant (p<0.001 vs baseline) and similar BP reduction both for SBP and DBP, with no difference 
between treatments; also the number patients who achieved a BP normalization was similar (82% with aliskiren vs 86% with amlodipine, p=0.42). 
Aliskiren induced a significant reduction in QTc dispersion (-10.5 ± 23.6 ms, p=0.03) and in QTmax (-11.9 ± 22.7 ms, p=0.02); the QTc dispersion 
change did not correlate with the change in BP. Amlodipine induced a smaller and non significant reduction in QTc (-8.4 ± 27.7 ms, p=0.07) and in 
QTmax (-7.1 ± 30.2 ms, p=0.08) and the QTc dispersion change showed a significant correlation with SBP change (r=0.459, p < 0.01).
Conclusions: aliskiren chronic treatment reduces QT dispersion in hypertensive diabetic patients and this effect is not related to the lowering of 
BP alone. This suggests that aliskiren has the potential to reduce severe arrhythmic complications in this type of patients.
